Supernus Pharmaceuticals Inc
Research Supernus Pharmaceuticals Inc (SUPN) on Bullrun: market cap USD 2.64B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSUPN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 2.64B
- Financial periodQ2 2026
- RevenueUSD 219.06M
- Net income-USD 58.37M
- Free cash flow-USD 5.38M
- Gross margin84.6%
Valuation Snapshot
latest market cap is USD 2.64B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 718.95M | -USD 38.60M | USD 45.99M | 89.6% | -0.68 | USD 128.45M | USD 40.98M | USD 1.06B |
| FY2024 | USD 661.82M | USD 73.90M | USD 171.23M | 88.2% | 1.32 | USD 69.33M | USD 34.27M | USD 1.04B |
| FY2023 | USD 607.52M | USD 1.30M | USD 110.53M | 86.2% | 0.02 | USD 75.05M | USD 41.53M | USD 921.52M |
| FY2022 | USD 667.24M | USD 60.70M | USD 116.41M | 86.9% | 1.04 | USD 93.12M | USD 401.44M | USD 886.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.64B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.86B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.02B | 27.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.58B | 74.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.93B | 55.7 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.55B | 29.8 | n/a | n/a |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Supernus Pharmaceuticals Inc's market cap?
Supernus Pharmaceuticals Inc's market capitalization is USD 2.64B.
What does Supernus Pharmaceuticals Inc do?
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.